• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home

Lenvatinib plus pembrolizumab show similar health-related quality-of-life outcomes in patients with advanced renal cell carcinoma compared to sunitinib

byJamie ParkandSamuel Chan
May 2, 2022
in Nephrology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The median follow-up period for health-related quality-of-life (HRQOL) outcomes analyses was 12.9 months

2. For all FKSI-DRS, EORTC QLQ-C30 GHS/QOL and EQ-5D visual analogue scale, the scores were similar between lenvatinib plus pembrolizumab versus sunitinib.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Based on the primary endpoint data from the CLEAR study, lenvatinib plus pembrolizumab showed promising efficacy safety data compared to sunitinib for patients with advanced renal cell carcinoma. This study presents the health-related quality-of-life (HRQOL) outcomes of the CLEAR study. The 3 HRQOL tools that this study utilized were the Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index – Disease Related Symptoms (FKSI-DRS), European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ – C30) global health status/quality of life (GHS/QOL) and EQ-5D-3. The mean change from baseline and time to definitive deterioration favoured the combination group. The time to first deterioration was similar between both study arms. Limitations to this study included the open-label nature of the study, no adjustments for multiple comparisons and the timing of sunitinib assessment at the end of the cycle coincided with off-treatment periods and could have led to better patient-reported health outcomes. Overall, this study demonstrated support the lenvatinib plus pembrolizumab as it has similar quality of life outcomes compared to standard of care.

Click to read the study in The Lancet Oncology

Relevant Reading: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

In-Depth [randomized controlled trial]: This was an open label, randomized, phase III study. Patients were eligible if they had advanced clear-cell renal cell carcinoma and scored 70% or higher on the Karnofsky performance status. Patients were excluded if they had previously received systemic anticancer therapy for renal cell carcinoma. A total of 1069 patients were enrolled to receive lenvatinib plus pembrolizumab (n=355) or lenvatinib plus everolimus (n=357)  or sunitinib (n=357). The demographic of all study groups was well-balanced. The median follow-up period for the health-related quality-of-life analysis (HRQOL) was 12.9 months (interquartile range [IQR]: 5.6-22.3). There were differences in the mean change from baseline between lenvatinib plus pembrolizumab versus sunitinib group (FKSI-DRS: -1.75 vs. -2.19; EORTC QLQ-C30 GHS/QOL: -5.93 vs.-6.73); EQ-5D-3: -4.96 vs. -6.64). For median time to deterioration between lenvatinib plus pembrolizumab versus sunitinib group, the values were 9.14 weeks versus 12.4 weeks (FKSI-DRS), 12.00 weeks versus 9.14 weeks (EORTC QLQ-C30 GHS/QOL) and 9.43 weeks versus 9.13 weeks (EQ-5D-3). For median time to definitive deterioration between lenvatinib plus pembrolizumab versus sunitinib group, the values were 134.14 weeks versus 117.43 weeks (FKSI-DRS), 114.29 weeks versus 75.14 weeks (EORTC QLQ-C30 GHS/QOL) and 124.86 weeks versus 74.86 weeks (EQ-5D-3).

RELATED REPORTS

#VisualAbstract: Combination therapy using conformation-specific KIT inhibitors associated with clinical benefit in patients with advanced gastrointestinal stromal tumors

Combination therapy using conformation-specific KIT inhibitors associated with clinical benefit in patients with advanced gastrointestinal stromal tumors

#VisualAbstract: Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: advanced renal cell carcinomalenvatinib and pembrolizumabsunitinib
Previous Post

High physical activity may have a role in increasing coronary artery calcification

Next Post

Ivosidenib and azacitidine showed significant clinical benefit in newly diagnosed IDH1-mutated acute myeloid leukemia

RelatedReports

#VisualAbstract: Combination therapy using conformation-specific KIT inhibitors associated with clinical benefit in patients with advanced gastrointestinal stromal tumors
StudyGraphics

#VisualAbstract: Combination therapy using conformation-specific KIT inhibitors associated with clinical benefit in patients with advanced gastrointestinal stromal tumors

July 20, 2021
Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Chronic Disease

Combination therapy using conformation-specific KIT inhibitors associated with clinical benefit in patients with advanced gastrointestinal stromal tumors

July 15, 2021
#VisualAbstract: Tocilizumab reduced COVID-19 disease related adverse health outcomes
StudyGraphics

#VisualAbstract: Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma

March 11, 2021
Galangin may sensitize apoptosis-resistant renal carcinoma cells [PreClinical]
Nephrology

Nivolumab and cabozantinib superior to sunitinib for advanced renal-cell carcinoma

March 10, 2021
Next Post
Prophylactic platelet transfusions prevent bleeding in hematologic cancers

Ivosidenib and azacitidine showed significant clinical benefit in newly diagnosed IDH1-mutated acute myeloid leukemia

Symptoms of posttraumatic stress disorder highly prevalent among family members of patients admitted to the intensive care unit with COVID-19

Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.